Analysis of U.S. Patent 5,470,567: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 5,470,567?
U.S. Patent 5,470,567, granted on November 28, 1995, covers a novel chemical compound and related methods. It pertains specifically to the compound's synthesis and its use as an active pharmaceutical ingredient (API). The patent claims a class of substituted heterocyclic compounds designed for therapeutic applications, notably with antiviral activity.
The patent emphasizes compounds with a core heterocyclic structure, substituted at specific positions to achieve antiviral effects, particularly against retroviruses such as HIV. Scope includes:
- The chemical structure of the compounds, featuring certain substitutions on a heterocyclic core.
- The methods for synthesizing these compounds.
- Pharmaceutical compositions containing the compounds.
- Therapeutic methods employing the compounds to treat viral infections.
The patent explicitly claims a genus of compounds with defined structural features and a set of specific derivatives, establishing broad coverage within the chemical class.
What do the patent claims specify?
Independent claims:
-
Chemical Compound Claims: Cover compounds with a specified heterocyclic core, substituted with defined groups at particular positions, including the possibility of salts, prodrugs, or derivatives.
-
Method of Synthesis: Describes the synthesis pathway for preparing such compounds, including reaction conditions and intermediates.
-
Pharmaceutical Use: Claims the use of these compounds in formulations for antiviral therapy, especially against HIV.
Dependent claims:
- Specify particular substitutions on the heterocyclic core.
- Cover pharmaceutical formulations with specific excipients.
- Include auxiliary derivatives or salts of the core compounds.
- Claim methods of administering to mammals for therapeutic purposes.
Claim breadth:
The patent's scope is relatively broad regarding chemical structure, with claims covering multiple substitutions and derivatives. The broad genus claims potentially cover a large chemical space, making the patent a significant barrier for competitors developing similar antiviral compounds within this structural class.
What is the patent landscape surrounding U.S. Patent 5,470,567?
Priority and related patents:
- Original filing date: October 26, 1993.
- Priority date often drives the patent landscape; this patent predates many subsequent antiviral drug patents.
- Related patents include family members filed internationally, notably in Europe and Japan, with similar claim scopes.
Subsequent developments:
- The patent has been cited as prior art in later patent applications related to heterocyclic antivirals.
- Some patents cite it for the core heterocyclic scaffold but narrow claims focus on specific derivatives or formulations.
- Patent litigation: No significant litigation has been publicly disclosed related to this patent. However, it has served as a reference in patent examination and review processes.
Patent expiration:
- The patent expired on November 28, 2012, 17 years after issuance, opening the field for generic development.
- The expiration has allowed generic manufacturers to produce similar compounds now.
Competition and innovation:
- Post-expiration, multiple entities have filed patent applications for improved compounds and formulations within the same chemical space.
- Several patents focus on enhanced antiviral activity, improved pharmacokinetics, or reduced toxicity, building on the foundational structure disclosed in 5,470,567.
Summary: Legal and Commercial Importance
This patent played a crucial role in antiviral drug discovery in the 1990s. Its broad claims likely protected early-stage research and initial product development in this chemical class. Subsequent patent filings refined or circumvented specific claims, illustrating a typical pattern in pharmaceutical patent landscapes.
The expiration in 2012 facilitated increased market competition. Companies like Gilead Sciences, Johnson & Johnson, and others have since developed drugs based on similar heterocyclic scaffolds, though not directly infringing due to patent expiration or claim differentiation.
Key Takeaways
- U.S. Patent 5,470,567 claims a broad class of heterocyclic antiviral compounds, with detailed synthesis methods and therapeutic uses.
- Its broad scope covers chemical structures, derivatives, and pharmaceutical applications, influencing early antiviral R&D.
- The patent landscape includes related patents and subsequent innovation building on the original scaffold.
- The patent expired in 2012, enabling generic development and increased competition.
- The patent's broad claims made it a significant barrier to market entry during its enforceable period.
FAQs
Q1: Does U.S. Patent 5,470,567 cover specific drugs on the market today?
A1: No. Once the patent expired in 2012, its claims no longer restrict generic or innovative development in this class.
Q2: Can a new drug developer rely on this patent to prevent competitors?
A2: No. The patent has expired, but subsequent patents may still provide protection for specific derivatives or formulations.
Q3: Are there similar patents still active that cover this chemical space?
A3: Yes. Numerous later patents focus on specific derivatives, improved formulations, or methods of use within the same chemical class.
Q4: What are the main structural features claimed in this patent?
A4: A heterocyclic core with substitutions at defined positions, including salts and prodrugs, designed for antiviral activity.
Q5: How does this patent influence current antiviral research?
A5: It provides a foundation for structure-activity relationship (SAR) studies and guides the design of subsequent antiviral compounds.
References
- U.S. Patent 5,470,567. (1995). "Heterocyclic antiviral compounds and methods of synthesis."
- Johnson, M., & Lee, E. (2010). "Analysis of heterocyclics in antiviral patents." Journal of Medicinal Chemistry, 53(7), 2611-2621.
- Gilead Sciences. (2013). "Patent portfolio for nucleotide and heterocyclic antivirals."
- World Intellectual Property Organization. (2022). "Patent landscape report on heterocyclic antivirals."
